ORPHA:2800
Extramammary Paget disease
Publications
3,159
Trials
12
Interventional, condition-specific
Researchers
1,086
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare skin tumor characterized by predominantly intraepithelial growth of an adenocarcinoma which may either arise primarily in the skin (primary extramammary Paget disease) or result from intraepithelial spread of a visceral carcinoma (secondary extramammary Paget disease). The lesion is typically located in the anogenital region, presenting as a scaly, oozing, pruritic or painful erythematous plaque often resembling eczema. It may exhibit an invasive component with a significant risk of lymph node metastasis.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0008177
- MeSH:D010145
- OMIM:167300
- UMLS:C0030186
- NCIT:C3302
Additional Mondo synonyms (6)
Extramammary Paget's disease · Paget disease Extramammary · Paget's disease of skin · Paget's disease of the skin · Paget's skin disease · extramammary Paget disease
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
3,159 matched papers (1,247 in last 10 years) Source
- Phenotype characterisedPresent
2 HPO annotations (e.g. Neoplasm; Eczematoid dermatitis) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
12 matched on ClinicalTrials.gov (8 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
4
Drugs / clinical candidates · MONDO_0008177
- DISITAMAB VEDOTIN·phase 2
- TORIPALIMAB·phase 2
- TRASTUZUMAB REZETECAN·phase 2
- IMIQUIMOD·unknown
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
3,159
3,159 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
3,159 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,247 in the last 10 years · low confidence
Phrase hits: 3,159 · MeSH hits: 0
Who's working on it?
1,086
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li H7 papers · 2026
Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
Papers in Europe PMC - 02Nakamura Y7 papers · 2026
Department of Dermatology, Keio University School of Medicine, Tokyo, Japan. Electronic address: yn1109@keio.jp.
Papers in Europe PMC - 03Zhang G7 papers · 2026
Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
Papers in Europe PMC - 04Yamazaki N6 papers · 2026
Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Papers in Europe PMC - 05Chen X5 papers · 2025
Department of Gastroenterology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China.
Papers in Europe PMC - 06Fukushima S5 papers · 2026
Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Papers in Europe PMC - 07Funakoshi T5 papers · 2024
Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.
Papers in Europe PMC - 08Kajihara I5 papers · 2026
Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Papers in Europe PMC - 09Namikawa K5 papers · 2025
Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Papers in Europe PMC - 10Ogata D5 papers · 2025
Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
12
interventional trials for this specific condition
12 interventional trials matched this specific condition name; 8 currently recruiting in our sample. 5 trials are registered for Paget disease, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
12 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 93.2th percentile).
low confidence · 93.2th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
12 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT03713203·RECRUITING·PAGETEX® Photodynamic Therapy Device for the Treatment of Extra Mammary Paget's Disease of the Vulva (EMPV).
Not reviewed·Conditions: Paget Disease of the Vulva · Paget Disease, Extramammary·Matched via name phrase
- NCT06791070·RECRUITING·A Study of RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum
Not reviewed·Conditions: Paget Disease, Extramammary · Scrotum Disease·Matched via name phrase
- NCT06683846·RECRUITING·Ivonescimab in the Treatment of Multiple Advanced Tumors
Not reviewed·Conditions: Pheochromocytoma/Paraganglioma · Rhabdomyosarcoma · Paget Disease, Extramammary · Renal Angiomyolipoma·Matched via name phrase
- NCT06561555·RECRUITING·A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.
Not reviewed·Conditions: Mammary or Extramammary Paget's Disease·Matched via name phrase
- NCT06684327·RECRUITING·Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors
Not reviewed·Conditions: Paget Disease, Extramammary · Rhabdomyosarcoma · Testicular Cancer · Penile Cancer·Matched via name phrase
- NCT05859074·RECRUITING·A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Not reviewed·Conditions: Cutaneous Squamous Cell Carcinoma · SCC - Squamous Cell Carcinoma · Basal Cell Carcinoma · BCC·Matched via name phrase
- NCT07117851·RECRUITING·A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease
Not reviewed·Conditions: Extramammary Paget Disease · Scrotum Disease·Matched via name phrase
- NCT06873815·RECRUITING·A Study of Fluorescein Sodium in People Undergoing Vulvectomy for Extramammary Paget's Disease (EMPD)
Not reviewed·Conditions: Extramammary Paget's Disease·Matched via name phrase
Broader category: Paget disease
5
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT03564483·RECRUITING·Gynecologic Extramammary Paget's Disease
Not reviewed·Conditions: Extramammary Paget's Disease · Extramammary Paget Disease · Paget Disease, Extramammary · Extramammary Paget's Disease of Vulva (Diagnosis)·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Extramammary Paget disease — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Extramammary Paget disease" OR "Extramammary Paget's disease" OR "Paget disease Extramammary" OR "Paget's disease of skin" OR "Paget's disease of the skin" OR "Paget's skin disease"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Extramammary Paget disease" OR "Extramammary Paget's disease" OR "Paget disease Extramammary" OR "Paget's disease of skin" OR "Paget's disease of the skin" OR "Paget's skin disease"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 12 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"Paget disease"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (3159) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T21:14:41.764Z
